Montelucaste Teva (Montelukast)

Montelukast, the active ingredient in Montelucaste Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to prevent asthma symptoms, control exercise‑induced bronchoconstriction, and relieve allergic rhinitis in adults and children.

GNH USA supplies Montelucaste Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU regulatory standards and is distributed through validated supply chains. Our quality assurance processes ensure batch consistency and compliance with pharmacopoeial specifications.

Montelucaste Teva, a leukotriene receptor antagonist, is indicated for several respiratory and allergic conditions.

Asthma prophylaxis: reduces frequency of asthma attacks and improves overall control. Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergens.

Montelucaste Teva may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness - Cough - Sore throat

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Neuropsychiatric events including mood changes or suicidal thoughts - Hepatic injury or elevated liver enzymes - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Montelucaste Teva, clinicians should consider several precautionary measures to ensure safe use.

Pregnancy: safety not established; discuss risks with healthcare provider. Liver impairment: use with caution and monitor hepatic function. Concomitant CYP3A4 inhibitors: may increase drug exposure; adjust as needed. Neuropsychiatric events: monitor patients for mood changes or suicidal thoughts. Store at room temperature: keep in original packaging, protect from moisture and heat.

Montelucaste Teva can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition can markedly increase montelukast levels. - Ketoconazole: potent CYP3A4 inhibitor may raise exposure and risk of side effects. - Phenobarbital: enzyme inducer may reduce montelukast concentrations, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Theophylline: may increase plasma levels; observe for toxicity signs. - Fluconazole: moderate CYP3A4 inhibition may modestly increase montelukast exposure.